相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Low Levels of Low-Density Lipoprotein Cholesterol and Blood Pressure and Progression of Coronary Atherosclerosis
Adnan K. Chhatriwalla et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm:: extended observations 2 years after trial closure
Peter S. Sever et al.
EUROPEAN HEART JOURNAL (2008)
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
Luigi Tavazzi et al.
LANCET (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rosuvastatin in older patients with systolic heart failure
John Kjekshus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)
John C. LaRosa et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of torcetrapib on the progression of coronary atherosclerosis
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of high-dose atorvastatin on hospitalizations for heart failure - Subgroup analysis of the treating to new targets (TNT) study
Kiran K. Khush et al.
CIRCULATION (2007)
Drug Insight: statins for nonischemic heart failure - Evidence and potential mechanisms
Michael J. Lipinski et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2007)
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Christopher P. Cannon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Efficacy and safe of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes - The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)
Robert H. Knopp et al.
DIABETES CARE (2006)
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study
BM Scirica et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level
BE Bleske et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure
S Sola et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
Haruo Nakamura et al.
LANCET (2006)
The effects of Atorvastatin (10 mg) on systemic inflammation in heart failure
D Mozaffarian et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure
D Tousoulis et al.
EUROPEAN JOURNAL OF HEART FAILURE (2005)
Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis
JG Robinson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure
CH Strey et al.
ATHEROSCLEROSIS (2005)
Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure
D Tousoulis et al.
ATHEROSCLEROSIS (2005)
Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure
D Tousoulis et al.
HEART (2005)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
Optimal low-density lipoprotein is 50 to 70 mg/dl - Lower is better and physiologically normal
JH O'Keefe et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy
K Node et al.
CIRCULATION (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
PS Sever et al.
LANCET (2003)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd et al.
LANCET (2002)
Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques - Implications for plaque stabilization
M Crisby et al.
CIRCULATION (2001)
分享论文
